Friday - July 31, 2026
Goodwin Guides Repertoire Immune Medicines on a Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases for $85 Million Upfront, Up to $1.84 Billion in Milestones, and Potential Tiered Royalties
January 30, 2026
BOSTON, Massachusetts, Jan. 30 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:

* * *

Goodwin Guides Repertoire Immune Medicines on a Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases for $85 Million Upfront, Up to $1.84 Billion in Milestones, and Potential Tiered Royalties

*

The Life Sciences team guided Repertoire Immune Medicines on entering a strategic collaboration . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products